Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression
Miriam Simón-Fuentes, Israel Ríos, Cristina Herrero, Fátima Lasala, Nuria Labiod, Joanna Luczkowiak, Emilia Roy-Vallejo, Sara Fernández de Córdoba-Oñate, Pablo Delgado-Wicke, Matilde Bustos, Elena Fernández-Ruiz, Maria Colmenares, Amaya Puig-Kröger, Rafael Delgado, Miguel A. Vega, Ángel L. Corbí, Ángeles Domínguez-Soto
Miriam Simón-Fuentes, Israel Ríos, Cristina Herrero, Fátima Lasala, Nuria Labiod, Joanna Luczkowiak, Emilia Roy-Vallejo, Sara Fernández de Córdoba-Oñate, Pablo Delgado-Wicke, Matilde Bustos, Elena Fernández-Ruiz, Maria Colmenares, Amaya Puig-Kröger, Rafael Delgado, Miguel A. Vega, Ángel L. Corbí, Ángeles Domínguez-Soto
View: Text | PDF
Research Article COVID-19 Immunology

MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression

  • Text
  • PDF
Abstract

Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19, are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (GM-CSF), which promote the generation of antiinflammatory/immunosuppressive MAFB+ (M-MØ) or proinflammatory macrophages (GM-MØ), respectively. The transcriptional profile of prevailing macrophage subsets in severe COVID-19 led us to hypothesize that MAFB shapes the transcriptome of pulmonary macrophages driving severe COVID-19 pathogenesis. We have now assessed the role of MAFB in the response of monocyte-derived macrophages to SARS-CoV-2 through genetic and pharmacological approaches, and we demonstrate that MAFB regulated the expression of the genes that define pulmonary pathogenic macrophages in severe COVID-19. Indeed, SARS-CoV-2 potentiated the expression of MAFB and MAFB-regulated genes in M-MØ and GM-MØ, where MAFB upregulated the expression of profibrotic and neutrophil-attracting factors. Thus, MAFB determines the transcriptome and functions of the monocyte-derived macrophage subsets that underlie pulmonary pathogenesis in severe COVID-19 and controls the expression of potentially useful biomarkers for COVID-19 severity.

Authors

Miriam Simón-Fuentes, Israel Ríos, Cristina Herrero, Fátima Lasala, Nuria Labiod, Joanna Luczkowiak, Emilia Roy-Vallejo, Sara Fernández de Córdoba-Oñate, Pablo Delgado-Wicke, Matilde Bustos, Elena Fernández-Ruiz, Maria Colmenares, Amaya Puig-Kröger, Rafael Delgado, Miguel A. Vega, Ángel L. Corbí, Ángeles Domínguez-Soto

×

Figure 6

MAFB contributes to the expression of profibrotic and neutrophil-recruiting chemokines in human macrophages exposed to SARS-CoV-2.

Options: View larger image (or click on image) Download as PowerPoint
MAFB contributes to the expression of profibrotic and neutrophil-recruit...
(A) Relative mRNA levels of the indicated genes in ΔMAFB M-MØ SARS, ΔMAFB GM-MØ SARS, and the corresponding controls, as determined by RNA-Seq. Mean ± SEM of 3 independent samples are shown. Padj of the comparison of macrophages with or without MAFB knockdown is shown. Statistical significance was calculated using the R-package DESeq2. (B) Production of the indicated soluble factors in ΔMAFB M-MØ SARS, ΔMAFB GM-MØ SARS, and the corresponding controls, as determined by ELISA. Mean ± SEM of 9 independent samples are shown (*P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001). Statistical significance was calculated using 1-way ANOVA with Tukey multiple-comparison test. (C and D) Concentration of CCL2, CCL18, SPP1, and CXCL10 in plasma from a cohort of 92 patients with COVID-19 grouped according to their OMS classification 14 days after hospital admission (C) or mortality (D). Horizontal lines represent the medians (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). For C, statistical significance (P values) was obtained using the Kruskal–Wallis test followed by pairwise comparisons using the Dunn’s test. For D, statistical significance (P values) was obtained using the 2-tailed Mann-Whitney U test. (E) ROC curve estimated using the plasma cytokine levels of SPP1, CCL18, and CXCL10 on hospital admission for patient survival or death during hospitalization. Death and survival predicted powers were estimated as 66.67% and 84.42%, respectively. P < 0.0001 for the parameters estimated. Values for AUC and its 95% CI are indicated.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts